Quizartinib Dihydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 17.7 mg , 26.5 mg
Reference Brands: Vanflyta (USA/EU)
Category:
Oncology Cancer Care
Quizartinib Dihydrochloride is available in Tablets
and strengths such as 17.7 mg , 26.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Quizartinib Dihydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Quizartinib Dihydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Quizartinib dihydrochloride is a targeted anticancer therapy used in the treatment of acute myeloid leukemia (AML), particularly in patients whose disease carries a mutation in the FMS-like tyrosine kinase 3 (FLT3) gene. AML is a rapidly progressing hematologic malignancy characterized by the uncontrolled growth of immature myeloid cells in the bone marrow and blood. Advances in molecular research have identified several genetic mutations that play a role in the development and progression of AML, with FLT3 mutations being among the most common and clinically significant targets for therapy.
Quizartinib is a second-generation FLT3 inhibitor designed to selectively block the activity of the FLT3 receptor tyrosine kinase. By inhibiting this abnormal signaling pathway, the drug helps reduce the proliferation of leukemia cells and supports better disease control when used as part of combination treatment strategies. Compared to earlier FLT3 inhibitors, quizartinib was developed to provide more targeted and potent inhibition of the FLT3 mutation.
The medicine is available in oral tablet form and is typically used in combination with standard chemotherapy for patients with newly diagnosed FLT3-ITD positive AML, followed by maintenance therapy. Quizartinib represents an important advancement in precision oncology, offering a mutation-directed treatment approach that helps improve outcomes in patients with specific genetic profiles of AML.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing